Categories: NewsPharmaceutical

Rexis Biotech Announces Strategic Partnership With 3CHI & Wefunder Crowdfunding Equity Raise

DOVER, DE / ACCESSWIRE / July 11, 2023 / Rexis Biotech Inc. (“REXIS”) is delighted to announce its continued growth and expansion into new markets through its latest strategic partnership with 3Chi, Inc.. Rexis will supply and manufacture several ingredients and finished consumer goods such as ready to drink beverages. These beverages will be sold into the Rexis national distribution network with contracted distribution value of $24,600,000 divided over the next 3 years.

3Chi is the world’s largest hemp derived, consumer packaged goods manufacturer and retailer; with national distribution into more than 35,000 retailers. 3Chi focuses on helping as many people as possible become the happiest and healthiest versions of themselves by giving them access to highly consistent cannabis products that did not previously exist.

Justin Journay, 3Chi CEO, stated, “We are extremely excited to announce our long term strategic partnership with Rexis. Rexis separates itself from the competition with their technology. Their Fused Polymorph Nano Fiber is several steps above of anything else that’s in the marketplace right now. The quality of product that we have gotten from them is unsurpassed.”

Keith Bushfield, Rexis CEO, Stated “This massive expansion of our strategic partnership with 3Chi combined with our Squared and Twist beverage brands makes Rexis undeniably the worlds largest hemp derived beverage manufacturer and distributor. Over the next 2 weeks, Rexis will begin delivering the first 1.7 million cans to our distribution and retail partners across the United States. This partnership also provides the perfect opportunity to announce the Rexis Biotech Inc. crowdfunding equity raise and corporate awareness campaign with WeFunder (www.wefunder.com/rexis). This crowdfunding campaign brings awareness to the Rexis platform while further building partner brand awareness.”

On Behalf of the Board of Directors of

Rexis Biotech Inc.
Keith Bushfield
CEO/President
Rexis Biotech Inc.
Tel: (403) 606-1498
Email: keith@rexissystems.com

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

About Rexis Biotech Inc.

Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams.

For more information, please visit: www.rexissystems.com

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE: REXIS BIOTECH

View source version on accesswire.com:
https://www.accesswire.com/767334/Rexis-Biotech-Announces-Strategic-Partnership-With-3CHI-Wefunder-Crowdfunding-Equity-Raise

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

7 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

7 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago